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Clear cell adenocarcinoma of the cervix is a rare tumor of the lower genital tract. It has been described in young
women with a history of intra uterine exposure to diethylstilbestrol. This tumor is characterized by a greater
tendency for late recurrences. In this article, we report the case of one exposed-patient who developed recurrence
as liver metastases, 24 years after the initial treatment. This case demonstrates the need and the importance for
continued follow-up in individuals prenatally exposed to diethylstilbestrol.
Keywords: Clear cell adenocarcinoma, Cervix, Diethylstilbestrol, RecurrenceBackground
Clear cell adenocarcinoma of the cervix is an uncom-
mon malignancy accounting for 4–9 % of cervical
adenocarcinomas which represent about 5–10 % of all
tumors of the cervix [1, 2]. It has been first described in
young women exposed in utero to Diethylstilbestrol
(DES) by Herbst et al. [3] and its incidence is in on the
order of 1.0 per 1000 exposed persons [4, 5]. Clear cell
adenocarcinomas of the lower genital tract have a
greater tendency to recur late and develop metastases in
distant sites more frequently than squamous cell carcin-
omas [6–8]. We report here the case of one patient who
developed recurrence 24 years after the initial treatment.
Case presentation
In July 1990, a 20-year-old woman presented with abnor-
mal vaginal bleeding. Her past medical history was only
significant for in utero DES exposure. Physical examin-
ation revealed a budding tumor involving the anterior lip
of the uterine cervix. The pelvic Computed Tomography
(CT) scan showed an enlargement of the cervix which
was deviated to the right. The mass came in contact
with the rectal wall but did not invade the bladder or
the parameters. Biopsy confirmed the diagnosis of clear* Correspondence: solangeadaniife@yahoo.fr
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evaluation including chest and abdominal scan was
normal. A laparotomy with bilateral ovarian transpos-
ition and iliac lymphadenectomy was performed. The
pathological examination of resected lymph nodes was
negative. After the initial surgery, the patient was
treated with brachytherapy (65 Grays). Because of an
insufficient tumor response to the brachytherapy, the
patient underwent two cervical conizations. After the
second conization, surgical margins were negative for
malignancy. The patient was then followed up regularly
with colposcopic evaluation and annual Pap smear.
Despite the conservative treatment, the patient was
unable to conceive. Fourteen years later in December
2004, she complained of metrorrhagia. Pelvic ultrasound
revealed an abnormal uterine mass of 28 mm. The pa-
tient underwent radical hysterectomy and right annex-
ectomy. The pathological analysis of the mass revealed a
leiomyoma and the right annex was normal. The patient
was followed up regularly and was considered to be free
of disease until February 2014 when she developed ab-
dominal pain and weight loss. Abdominal CT scan
showed multiple hepatic masses and peritoneal carcin-
omatosis. A hepatic percutaneous biopsy revealed a tumor
with tubular pattern consisting of large and polygonal cells
with clear or eosinophilic cytoplasm CK7+, CK20-, TTF1-,
ER-, PR-, HER2-, CDX2- and CK5/6- (Fig. 1). Based on
these characteristics, the tumor was considered as
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Fig. 1 Histological findings. Biopsy of a liver metastasis showing
glandular tumor mass composed of tubular structures with large
cells and clear cytoplasm (Hematoxylin and eosin staining (a) and
(b) with high magnification)
Fig. 2 Before and after the treatment. CT scans showing hepatic
metastases before the treatment (a), and the tumor size reduction
after 3 cycles of chemotherapy (b) and after 6 cycles (c)
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ease including a FDG-PET-scan confirmed hepatic and
peritoneal lesions. The patient received combination
chemotherapy regimen including weekly paclitaxel
(80 mg/m2), carboplatin (AUC = 5) and bevacizumab
(7.5 mg/kg) both administered every three weeks. To
date, she has received 7 cycles of this combination with
excellent tolerance and the follow up CT scans have
showed a partial response with reduction of tumor size
after 3 and 6 cycles (Fig. 2).
Discussion
Diethylstilbestrol (DES) is an oral synthetic nonsteroidal
estrogen that was used to prevent miscarriage, premature
birth and other pregnancy complications between 1938
and 1971 in the United States [9] and until early 1980’s in
various European countries [9, 10]. Exposure to DES
during a critical period of organogenesis disturbs the
developing uterine muscle layers, causes abnormalitiesof the uterotubal junction, and prevents stratification of
the vaginal epithelium and resorption of vaginal glands,
resulting in vaginal adenosis [10]. In female offspring,
in utero exposure to DES has been associated with po-
tential risks of cervicovaginal clear cell adenocarcin-
oma, congenital anomalies and epithelial changes of the
reproductive tract, subfertility and adverse pregnancy
outcomes, earlier age at menopause, breast cancer and
cervical intra epithelial neoplasia [10].
DES related clear cell adenocarcinoma usually occurs
between the age of 15 and 27 with a median of 19 years
[4] and have a predilection for the ectocervix and upper
third of the vagina [11]. Pathologically, the tumors can
display solid, tubular, cystic and papillary patterns or
mixed patterns [12, 13] with the tubular-cystic pattern
being the most common presentation [13]. Survival rates
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cell adenocarcinoma with papillary and tubulocystic
features while tumors with more solid pattern have less
favorable prognosis [14]. Most cases of clear cell car-
cinoma related to DES exposure have been diagnosed
at stage one or two [5]. Patients with early stage are
highly curable with surgery or radiotherapy or combin-
ation of both modalities [15–17]. However, clear cell
adenocarcinoma can also be diagnosed in unexposed
women. It can occur in older women [12, 18] and in
about 25% of cases in young women, there is no history
of maternal medication [19].
Most recurrences of clear cell adenocarcinoma of the
vagina and cervix are diagnosed within the 3 years after
primary tumor treatment [8] but late recurrences have
been reported with few cases 8 years after initial diagno-
sis [7, 14, 20, 21]. To date the latest recurrence reported
in DES exposed patients is 19 years after initial therapy
[11]. Here, we present the case of a woman with intra
uterine DES exposure who developed recurrence as dis-
tant metastases without local relapse, 24 years after ini-
tial curative treatment. In 1991, Goodman and coll
reported a local recurrence of clear cell adenocarcinoma
of the vaginal remnant presenting 20 years after initial
surgery. Basing on the 20 years disease -free period, the
absence of nodal, lymphatic or vascular involvements
and the absence of distant spread in their case, they sug-
gested a new primary tumor rather than a late recurrence
[22]. In our patient, the absence of local relapse suggests
the possibility that quiescent tumor cell may have been
initially present in the liver and peritoneum and became
activated after a prolonged interval and/or evolved slowly
and finally became symptomatic.
In the cases reported by Herbst et al. [8], recurrences
were more frequent in the pelvis (60 %), the lungs
(36 %) and supraclavicular lymph nodes (12 %). One pa-
tient was reported with cerebellar metastases [20] but
liver metastases from DES related clear cell adenocarcin-
oma of cervix have never been described. Because of a
similar histological morphology, this diagnosis can be
confused with that of primary clear cell carcinoma of
liver, which is a particular and rare histological type of
hepatocellular carcinoma [23, 24]. However, most of
primary clear cell carcinoma of the liver occur in patients
with liver cirrhosis [25] and the cases reported in patients
with normal liver are uncommon [26]. Nevertheless, for
the present case, immunostaining of biopsy samples ex-
cluded primary clear cell carcinoma of liver.
Local recurrences of clear cell adenocarcinoma of the
cervix can be effectively treated with surgery, radiother-
apy or combined modality [21]. Surgery or radiation
therapy can be used to treat also limited metastatic recur-
rence. In disseminated recurrent disease, systemic chemo-
therapy including various cytotoxic drugs (alkylant agents,5-fluorouracil, adriamycine, vinca-alcaloids, actinomycine
D, cisplatin) or progestational agents has been used [8, 21]
but no effective regimen is currently considered as the
reference treatment [8, 21]. However paclitaxel has
been administrated to one patient, and has permitted
to obtain stable disease on CT scan and the decrease of
the initially high CA 125 tumor marker [11]. Our patient
is being treated with a combination of paclitaxel, carbo-
platin and bevacizumab which is an anti-angiogenic
(anti Vascular Endothelial Growth Factor) monoclonal
antibody. This regimen is active, inducing a clinical im-
provement (symptom disappearance) and a morphologic
partial response.Conclusions
To summarize, this case represents the longest reported
disease-free interval till recurrence and the first descrip-
tion of metastatic liver disease of DES related clear cell
adenocarcinoma of the cervix. It reemphasizes the ne-
cessity of long term surveillance of DES exposed
women and confirms previous reports recommending
the importance of frequent follow-up examination not
only of the pelvis but also of all distant potential sites
of metastasis. It also shows that treatment with pacli-
taxel, carboplatin and bevacizumab can be an effective
and safe therapeutic option for treating recurrence of
this rare tumor.Consent
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